Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omega-3 polyunsaturated fatty acids in peripheral arterial disease: effects on endothelial function
2009-018190-31Phase 2Completed
- Sponsor
- Medical University of Vienna
- Start
- Jul 2010
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in arteriosclerosis obliterans and intermittent claudication (IC) comparing Omacor with Placebo (2 arms). Primary endpoint: Change in endothelial function (FMD) at 12 weeks. Started Jul 2010; status: completed.
02
Drugs
omega-3-acid triglycerides
03
Conditions
arteriosclerosis obliteransintermittent claudication (IC)
Beyond the preview
Go deeper on 2009-018190-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-018190-31.